Octreotide and Inotuzumab Ozogamicin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Octreotide
Inotuzumab Ozogamicin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
The concomitant use of inotuzumab ozogamicin with drugs that cause QT-interval prolongation increases the risk of QT prolongation. Discontinuation or the use of alternative drugs that do not prolong the QT-interval is recommended while the patient is taking inotuzumab ozogamicin. When concomitant use of drugs known to prolong QT-interval is unavoidable, obtain an electrocardiogram and electrolyte levels prior to therapy initiation, after the initiation of the drug known to prolong the QT-interval, and as clinically indicated during treatment1.
Why it happens (mechanism)
Additive QT interval prolongation
Common questions
Can I take Octreotide and Inotuzumab Ozogamicin together?
Increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Octreotide and Inotuzumab Ozogamicin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Octreotide or Inotuzumab Ozogamicin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: BESPONSA(TM) intravenous injection, inotuzumab ozogamicin intravenous injection. Pfizer Inc (per FDA), Philadelphia, PA, 2017. DailyMed
Keep reading about Octreotide
Keep reading about Inotuzumab Ozogamicin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist